WAYNE -
This sterile, single-use tray includes all the components required for the IO access procedure, enabling a streamlined clinician workflow.
The new Arrow EZ-IO Procedure Tray includes the first FDA-cleared sterile, single-use, battery-powered driver, providing clinicians with an IO access option that can be used in a sterile field in the operation room and any other area of the hospital that requires a sterile field. The tray is packaged with an Arrow EZ-IO Intraosseous Needle Set (15mm, 25mm, or 45mm), which is designed to help ensure a fast,1 precise, and steady insertion. Additional components include:
Delayed vascular access can result in treatment delays, which can lead to adverse outcomes.2-5 The Arrow EZ-IO Intraosseous Access System can be used when intravenous access is difficult or impossible to obtain in emergent, urgent, or medically necessary cases. In a recent survey of hospital-based clinicians, 65% recalled situations where their IO device was not accessible during a time-critical difficult vascular access situation.6 More than 75% of clinicians surveyed agree that a single-use tray would increase the accessibility and convenience of IO access devices.6 The new Arrow EZ-IO Procedure Tray was designed for compact storage on hospital shelving and is small enough to fit in any code cart.
Clinicians now have a choice between the reusable Arrow EZ-IO Power Driver and the new single-use tray. 'The new Arrow EZ-IO Procedure Tray was designed to optimize efficiency in gaining fast vascular access while increasing the accessibility of the EZ-IO System,' said
About
As a global provider of medical technologies,
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties, and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the
Contact:
Vice President
Tel: 610-948-2836
Email: investors.teleflex.com
(C) 2024 Electronic News Publishing, source